Madrid (Spain) and Carros (France), February 23, 2021 – Algenex SL, a VC-backed biotechnology company delivering disruptive technologies for recombinant biologics production, and Virbac, the sixth largest animal health company worldwide, today announce that they have entered into an international licensing agreement for the development and commercialization of a CrisBio^®-based vaccine in a major swine indication.

The vaccine will be developed jointly and manufactured using CrisBio^®, Algenex’ proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. CrisBio^® represents a new paradigm in biologics production, offering a quick, linearly scalable solution to meet the global demand for recombinant protein production without significant capex investment. 

“This new collaboration with Virbac, one of the global leaders in animal health, is another important milestone for Algenex and a further validation of our unique CrisBio^® technology and its potential to transform vaccine production in major indications across animal health,” said Claudia Jiménez, CEO of Algenex.

“With this partnership, we will benefit from the experience of Algenex, and by providing a simple, scalable and cost-effective alternative to current bioreactor-based expression technologies on the market, we should be able to increase our footprint in the farm animals’ vaccine market” said Sébastien Huron, CEO, Virbac group.

Commercial and financial terms of the agreement were not disclosed. The agreement covers all global markets excluding Poland and Italy.